NASDAQ : PVLA
Palvella Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 151.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.18B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.11B |
| Enterprise Value | 1.88B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.41M |
| Shares Outstanding | 14.41M |
| Shares Change (YoY) | +83.69% |
| Shares Change (QoQ) | +9.71% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 91.87% |
| Float | 10.70M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.70 |
| P/TBV Ratio | 9.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 21.18 |
| Quick Ratio | 21.01 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.60 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.63% |
| Return on Assets (ROA) | -22.05% |
| Return on Invested Capital (ROIC) | -23.92% |
| Return on Capital Employed (ROCE) | -23.90% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.13M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | +94.43% |
| 50-Day Moving Average | 141.47 |
| 200-Day Moving Average | 126.93 |
| Relative Strength Index (RSI) | 59.55 |
| Average Volume (20 Days) | 229,150 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.41M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 16.71% |
| Short % of Float | 22.49% |
| Short Ratio (days to cover) | 9.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.74M |
| Pretax Income | -61.70M |
| Net Income | -61.70M |
| EBITDA | n/a |
| EBIT | -57.74M |
| Earnings Per Share (EPS) | -$4.90 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 250.58M |
| Total Debt | 22.64M |
| Net Cash | 227.94M |
| Net Cash Per Share | $15.82 |
| Equity (Book Value) | 216.87M |
| Book Value Per Share | 15.06 |
| Working Capital | 241.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -36.51M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -36.51M |
| FCF Per Share | -$2.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -83.69% |
| Shareholder Yield | -83.69% |
| Earnings Yield | -3.35% |
| FCF Yield | -1.73% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $228.40 |
| Price Target Difference | 56.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |